One hundred years of lung cancer - PubMed (original) (raw)
Review
. 2005 Sep 1;172(5):523-9.
doi: 10.1164/rccm.200504-531OE. Epub 2005 Jun 16.
Affiliations
- PMID: 15961694
- DOI: 10.1164/rccm.200504-531OE
Review
One hundred years of lung cancer
Stephen G Spiro et al. Am J Respir Crit Care Med. 2005.
Abstract
A hundred years ago, lung cancer was a reportable disease, and it is now the commonest cause of death from cancer in both men and women in the developed world, and before long, will reach that level in the developing world as well. The disease has no particular symptoms or signs for its detection at an early stage. Most patients therefore present with advanced stage IIIB or IV disease. Screening tests began in the 1950s with annual chest x-ray films and sputum cytology but they resulted in no improvement in overall mortality compared with control subjects. The same question is now being asked of spiral low-dose computed tomographic scanning. There have been big refinements in the staging classification of lung cancer and advances in stage identification using minimally invasive technology. Postsurgical mortality has declined from the early days of the 1950s but 5-year cure rates have only barely improved. The addition of chemotherapy to radical radiotherapy, together with novel radiotherapy techniques, is gradually improving the outcome for locally advanced, inoperable non-small cell lung cancer. Chemotherapy offers modest survival improvement for patients with non-small cell lung cancer, the modern agents being better tolerated resulting in an improved quality of life. The management of small cell lung cancer, which appeared so promising at the beginning of the 1970s, has hit a plateau with very little advance in outcome over the last 15 years. The most important and cost-effective management for lung cancer is smoking cessation, but for those with the disease, novel agents and treatment approaches are urgently needed.
Similar articles
- 100 years of lung cancer.
Pirozynski M. Pirozynski M. Respir Med. 2006 Dec;100(12):2073-84. doi: 10.1016/j.rmed.2006.09.002. Epub 2006 Oct 23. Respir Med. 2006. PMID: 17056245 Retracted. Review. - [Lung cancer - historical development, current status, future prospects].
Goeckenjan G. Goeckenjan G. Pneumologie. 2010 Sep;64(9):555-9. doi: 10.1055/s-0030-1255636. Epub 2010 Sep 8. Pneumologie. 2010. PMID: 20827638 German. - Lung cancer screening results in the National Cancer Institute New York study.
Melamed MR. Melamed MR. Cancer. 2000 Dec 1;89(11 Suppl):2356-62. doi: 10.1002/1097-0142(20001201)89:11+<2356::aid-cncr8>3.3.co;2-q. Cancer. 2000. PMID: 11147612 Clinical Trial. - Lung cancer--where are we today? Current advances in staging and nonsurgical treatment.
Spiro SG, Porter JC. Spiro SG, et al. Am J Respir Crit Care Med. 2002 Nov 1;166(9):1166-96. doi: 10.1164/rccm.200202-070SO. Am J Respir Crit Care Med. 2002. PMID: 12403687 Review. - [Lung cancer--review].
Gudbjartsson T, Smáradottir A, Skúladóttir H, Grímsson HN, Hardardóttir H, Björnsson J, Hannesson P, Haraldsdóttir SO, Jónsson S. Gudbjartsson T, et al. Laeknabladid. 2008 Apr;94(4):297-311. Laeknabladid. 2008. PMID: 18460729 Review. Icelandic.
Cited by
- Genetic polymorphisms in the vitamin D pathway in relation to lung cancer risk and survival.
Kong J, Xu F, Qu J, Wang Y, Gao M, Yu H, Qian B. Kong J, et al. Oncotarget. 2015 Feb 10;6(4):2573-82. doi: 10.18632/oncotarget.2951. Oncotarget. 2015. PMID: 25544771 Free PMC article. - Time courses and value of circulating microparticles in patients with operable stage non-small cell lung cancer undergoing surgical intervention.
Tseng CC, Wang CC, Hsiao CC, Lu HI, Leu S, Chang HC, Huang KT, Fang WF, Chen YM, Liu SF, Yang CT, Lin MC, Yip HK. Tseng CC, et al. Tumour Biol. 2016 Sep;37(9):11873-11882. doi: 10.1007/s13277-016-5047-5. Epub 2016 Apr 8. Tumour Biol. 2016. PMID: 27059732 - [MRI in staging of lung cancer].
Hintze C, Biederer J, Wenz HW, Eberhardt R, Kauczor HU. Hintze C, et al. Radiologe. 2006 Apr;46(4):251-4, 256-9. doi: 10.1007/s00117-005-1334-7. Radiologe. 2006. PMID: 16440188 Review. German. - Anti-cancer effects of 3,5-dimethylaminophenol in A549 lung cancer cells.
Lin PY, Chang YJ, Chen YC, Lin CH, Erkekoglu P, Chao MW, Tseng CY. Lin PY, et al. PLoS One. 2018 Oct 11;13(10):e0205249. doi: 10.1371/journal.pone.0205249. eCollection 2018. PLoS One. 2018. PMID: 30307971 Free PMC article. - Decreased Levels of Histidine-Rich Glycoprotein in Advanced Lung Cancer: Association with Prothrombotic Alterations.
Winiarska A, Zareba L, Krolczyk G, Czyzewicz G, Zabczyk M, Undas A. Winiarska A, et al. Dis Markers. 2019 Mar 3;2019:8170759. doi: 10.1155/2019/8170759. eCollection 2019. Dis Markers. 2019. PMID: 30944671 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical